Journal
NUTRIENTS
Volume 13, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/nu13093143
Keywords
inflammatory bowel disease; gut microbiota; bile acids; bile acid-activated receptors; therapy
Categories
Funding
- National Natural Science Foundation of China [82070545, 81970477]
- Key Project of Science and Technology Pillar Program of Tianjin [20YFZCSY00020]
Ask authors/readers for more resources
Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory disorder of the gastrointestinal tract, associated with dysbiosis of gut microbiota and bile acids, leading to impaired gut barrier and immune function. Restoring gut microbiota and bile acids can alleviate symptoms of IBD.
Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory disorder of the gastrointestinal tract, with increasing prevalence, and its pathogenesis remains unclear. Accumulating evidence suggested that gut microbiota and bile acids play pivotal roles in intestinal homeostasis and inflammation. Patients with IBD exhibit decreased microbial diversity and abnormal microbial composition marked by the depletion of phylum Firmicutes (including bacteria involved in bile acid metabolism) and the enrichment of phylum Proteobacteria. Dysbiosis leads to blocked bile acid transformation. Thus, the concentration of primary and conjugated bile acids is elevated at the expense of secondary bile acids in IBD. In turn, bile acids could modulate the microbial community. Gut dysbiosis and disturbed bile acids impair the gut barrier and immunity. Several therapies, such as diets, probiotics, prebiotics, engineered bacteria, fecal microbiota transplantation and ursodeoxycholic acid, may alleviate IBD by restoring gut microbiota and bile acids. Thus, the bile acid-gut microbiota axis is closely connected with IBD pathogenesis. Regulation of this axis may be a novel option for treating IBD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available